|
US2019269627A1
|
|
Memantine combinations and use
|
|
WO2018039159A1
|
|
Muscarinic m2-antagonist combination
|
|
WO2017147104A1
|
|
Muscarinic m2-antagonist combinations
|
|
AU2016231489A1
|
|
Composition for treating dementia
|
|
AU2016231493A1
|
|
Composition for treating dementia
|
|
US2018250270A1
|
|
Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
|
|
US2016375001A1
|
|
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
WO2017044714A1
|
|
Muscarinic combinations and their use for combating hypocholinergic disorders of the central nervous system
|
|
EP3324966A1
|
|
Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
|
|
US2018050008A1
|
|
Oxybutynin transdermal therapeutic system muscarinic agonist combination
|
|
EP3265466A1
|
|
Peripheral-anticholinergic muscarinic agonist combination
|
|
EP3265067A1
|
|
Oxybutynin-xanomeline transdermal therapeutic system combinations
|
|
WO2016112263A1
|
|
Oxybutynin transdermal therapeutic system combination
|
|
AU2015213396A1
|
|
Method and composition for treating Alzheimer-type dementia
|
|
AU2014277685A1
|
|
Composition for treating dementia
|
|
US2014288057A1
|
|
Method and composition for treating alzheimer-type dementia
|
|
KR20200065113A
|
|
Anticholinergic neuroprotective composition and methods
|
|
EP2882711A1
|
|
Piperidinium quaternary salts
|
|
MX345236B
|
|
Method and composition for treating alzheimer-type dementia.
|
|
AU2009229372A1
|
|
Use and composition for treating dementia
|
